Background/Aims: TNF-α receptor-associated factor (TRAF)-interacting protein with a forkhead-associated (FHA) domain (TIFA) may mediate the impact of TRAF on the development of lung cancer. The current study was conducted to investigate the expression of TIFA in lung adenocarcinoma and its potential role in the regulation of cancer cell proliferation and migration, and its influence on patient survival. Methods: Specimens of lung adenocarcinoma tissues and their adjacent normal lung tissues were obtained from 116 patients who underwent surgical resection of lung cancer. The expression of TIFA in the lung tissues was examined by immunohistochemistry, immunoblotting, and real-time RT-PCR in four different lung cancer cell lines and one normal bronchial epithelial cell line (BEAS-2B). TIFA was silenced by RNAi technique, and cell proliferation was then assessed by the CCK8 method. Furthermore, cell migration was determined by wound-healing trans-well and wound-healing migration assays. Additionally, cell-cycle arrest and apoptosis were assessed by flow cytometry analysis. Results: TIFA was positively detected in 63 (54.3%) out of 116 lung adenocarcinoma specimens, which was significantly higher than the respective rate established in normal tissues adjacent to the tumor (30.1%, p < 0.05). The overall survival rate was significantly lower in the patients with positive TIFA expression than that in the patients with negative TIFA expression (p < 0.05). TIFA was also highly expressed in the lung cancer cell lines (H1299, H1975, and HCC827) tested. It is noteworthy that siRNA suppressed the expression of TIFA, which contributed to the attenuation of cell proliferation and migration, but promoted cell-cycle arrest and apoptosis. Furthermore, the silencing of TIFA caused upregulation of p53, p21, and cleaved-caspase-3, but downregulation of Bcl-2, cyclin D1, and CDK4, as well as phosphorylation of IKKß, IκB, and p65. Conclusions: TIFA may serve as a biomarker in the prediction of lung adenocarcinoma. Furthermore, TIFA may modulate lung cancer cell survival and proliferation through regulating the synthesis of apoptosis-associated proteins.
The primary antibody used at the concentration recommended by the manufacturer was allowed to react with target proteins overnight at 4 °C. After washing with PBS-T, the membrane was incubated with HRPconjugated 2 nd antibody at room temperature for 1.5 h. Further, after washing, the targeted protein bands were visualized using ECL detection. GAPDH was utilized as a loading control, and the intensity of each band was quantified using image analysis software (ImageJ, National Institutes of Health, Bethesda, MD, USA).
Immunocytochemistry
Cells were cultured on cover slips and fixed with 4% methanol at 4 °C for 20 min. After washing, the cells were permeabilized with 0.2% Triton X-100 for 10 min at room temperature. Then, blocking was performed with goat serum, and anti-p65-antibody (Abcam, Cat #: ab16502) was applied overnight at 4 °C. The second antibody was added on the next day, followed by visualization of the protein expression using DAB staining and nuclear counterstaining with hematoxylin.
Real-time RT-PCR
The expression of TIFA mRNA was quantified by real-time RT-PCR. Briefly, total RNA was extracted from the cell lines using TRIzol reagent. After quantification, a total of 10 ng RNA was used for cDNA synthesis, followed by real-time PCR using One Step SYBR® PrimeScript TM RT-PCR Kit II according to the manufacturer's instructions. GPDH was employed as an internal control. The sequences of the primers used were as follows: TIFA-forward: 5'-ATGACCAGTTTTGAAGATGCTG-3'; TIFA-backward: 5'-TCCCAAAGCAGTTCTCCGACAG-3'; GAPDH-forward: 5'-TGTGGGCATCAATGGATTTGG-3'; GAPDH-backward: 5'-ACACCATGTATTCCGGGTCAAT-3'. Relative quantification of TIFA mRNA was conducted using the 2 -ΔΔCT method, followed by normalization using the internal control.
RNAi suppressed TIFA expression H1975 and HCC827 cells were plated at a density of 2 x 10 5 per a 60-mm dish. After 24-h culture, the cell culture medium was changed to Opti-MEM, and the cells were incubated for 2 h. The cells were then transfected with TIFA-siRNA or control-siRNA (50 µL) in 1.5 mL of Opti-MEM medium and 60 µL of Lipofectamine 2000 in 1.5 mL of Opti-MEM (total 3 mL of Opti-MEM) for 4 h. After brief washing with PBS, the cells were cultured for additional 48 h in 10%FCS-DMEM medium.
Cell proliferation assay
Cell proliferation was assessed using the CCK8 method following the manufacturer's instructions (Beyotime Biotechnology). Briefly, the cells were plated into a 96-well tissue culture plate at a density of 10 5 cells/well in 100 µL of cell culture medium. Further, cell proliferation was assessed on day 1, 2, 3, 4, and 5 by adding 10% CCK8 and incubation for 4 h. The optical density was measured at a wavelength of 450 nm. Medium plus CCK8 without cells was used as a blank sample, and the rate of cell proliferation was calculated.
Flow cytometry analysis for an assessment of cell-cycle arrest and apoptosis
Cell-cycle arrest and apoptosis were assessed by flow cytometry. Briefly, after transfection with TIFAsiRNA or control-siRNA (1-5 x10 6 cells each condition), cells were harvested by trypsinization and pelleted by centrifugation at 1000 rpm x 5 min. The cells were then washed once with 3 mL of PBS, followed by fixation with 70% ethanol at 4 °C for 2 h. After washing with PBS, the cells were stained with 1 µg/mL of propidium iodide (PI) in 1 mL of PBS at 4 °C for 30 min. Further, their cell cycle was examined by flow cytometry.
Apoptosis was evaluated using an Annexin-V kit following the manufacturer's instructions. Briefly, after trypsinization, the cells were pelleted and washed once with cold PBS, followed by centrifugation at 4 °C (2000 rpm x 5 min). The cells (1-5 x 10 6 cells each condition) were then re-suspended with 300 µL of binding buffer, followed by the addition of 5 µL of Annexin-V-FITC solution and incubation at room temperature in the dark for 15 min. The nuclei were stained with 5 µL of PI for 5 min. Finally, another 200 µL of binding buffer was added, and apoptosis was evaluated by flow cytometry.
Trans-well migration and wound-healing assay
For the trans-well assay, each well was coated with 30 µL of Matrigel for 2 h at 37 °C. Cells were then added into the top wells at a density of 5 x 10 5 cells/mL, 100 µL/well. In the bottom well, medium containing 20% FCS was added as a chemoattractant (500 µL/well). Further, the cells were incubated and allowed to migrate for 24 h. On the next day, the Matrigel and non-migrated cells in the top wells were wiped off, and the migrated cells were air-dried and transferred onto a 24-well plate. Crystal violet (1%) was then added into the 24-well plate (500 µL/well), followed by incubation at 37 °C for 30 min. After washing with PBS, the number of migrated cell was determined by counting under a high-power field (200 x); the procedure was performed in three different fields per well.
To conduct the wound-healing assay, cells were plated into a 6-well tissue culture plate and allowed to reach 60% confluence. Cell layer was wounded with a pipette tip, and the floating cells were removed by washing once with PBS. The cells were then cultured in normal medium for 24 h. After fixation, the woundhealing was assessed by measuring the distance between the lines of the wounded area under a microscope at 100 x magnification.
Statistical analysis
Statistical analysis was performed using SPSS23.0 software. Data were expressed as mean ± standard deviation (SD). Student's t-test or one-way ANOVA were employed to examine the difference among groups. A p-value < 0.05 was considered significant.
Results

TIFA expression in the lung cancer specimens
A total of 63 (54.3%) lung cancer specimens out of the 116 specimens from lung cancer tissues and their adjacent normal lung tissues, were strongly positive (Fig 1A and 1B) or weakly positive to TIFA (Fig. 1C and 1D ), whereas most of the samples from the adjacent lung tissues were TIFA-negative ( Fig. 1E and 1F) , and less than 35 of them (30.1%) were positive. A significant difference was found in TIFA positivity between the two groups (p < 0.05). As can be observed in Table 1 , the patients with positive TIFA expression were with a later stage (III-IV) and lower differentiation of cancer as well as a higher death rate (p < 0.05).
The results of the univariate regression analysis of the relationship of TIFA expression and patient's general information, and the pathological characteristics of lung adenocarcinoma (Table 2) indicated that the expression level of TIFA in the lung cancer tissues was associated 
Role of TIFA in cancer cell proliferation and survival
To investigate the role of TIFA in the regulation of cancer cell proliferation and metastasis, four different lung cancer cell lines (A549, H1299, H1975, and HCC827) were used for in vitro study and compared with a line of immortalized normal bronchial epithelial cells (BEAS2B). The expression levels of TIFA protein ( Fig.  3A and 3B ) in the adenocarcinoma cell lines were significantly higher than they were in the normal cell line (0.84 ± 0.19 in HCC827, 0.91 ± 0.17 in H1975, and 0.60 ± 0.13 in H1299 vs 0.38 ± 0.08 in BEAS2B, p < 0.05 or 0.01). Consistently, the expression of TIFA mRNA ( Fig. 3C ) was also significantly higher in the adenocarcinoma cells lines than in the normal cell line (1.33 ± 0.05 in HCC827, 1.36 ± 0.09 in H1975, 1.21 ± 0.06 in H1299, and 1.08 ± 0.05 in A549 vs 1.00 ± 0.07 in BEAS2B, p < 0.05 or 0.01).
Additionally, using RNAi, we found that the expression of TIFA was suppressed in the H1975 and HCC827 cancer cell lines (Fig. 4) . The suppression of TIFA by siRNA in the two above-mentioned cell lines resulted in significant inhibition of cell proliferation from day 2 to day 5 ( Fig. 5A and 5B, respectively, p < 0.05). Furthermore, this inhibitory effect exerted by siRNA lines led to the apoptosis of the cancer cell, evidenced by the increased Annexin- V-positive in the cells lacking TIFA (H1975: 33.4 ± 3.8%; HCC827: 34.8 ± 2.6%), whereas no such effect was observed in the control cells (H1975: 8.8 ± 5.3%, Fig. 6A and 6B, p < 0.05; HCC827: 10.6 ± 1.1%, Fig 6C and 6D , p < 0.05). Cell cycle examination by flow cytometry also confirmed that the percentages of G0/G1 stage cells were increased in H1975 (78.3 ± 1.8%) and HCC827 (79.6 ± 3.8%) after the transfection with TIFA-siRNA and were significantly higher than those in the cells transfected with control-siRNA (56.3 ± 3.7% and 60.3 ± 3.7%, respectively, p < 0.05, Fig. 7 ).
Role of TIFA in the modulation of cancer cell migration
The suppression of TIFA by siRNA in the H1975 or HCC827 cell lines resulted also in a significant reduction in cell migration (H1975: 14.0 ± 3.5 cells/HPF vs 35.0 ± 2.5 cells/ HPF, p < 0.05; HCC827: 15.6 ± 2.1 cells/HPF vs 28.3 ± 2.5 cells/HPF, p < 0.01, Fig. 8A and  8B) . Furthermore, the wound-healing assay revealed that the cells lacking TIFA had a more significantly reduced ability of wound-healing (H1975: 228.0 ± 2.5 µm; HCC827: 296.7 ± 4.5 µm) than the control lung cancer cells, in which TIFA was overexpressed (H1975: 131.3 ± 7.6 µm, Fig 9A and 9B ; HCC827: 190.0 ± 2.9 µm, Fig 9C and 9D, p < 0.01, respectively) . Effect of TIFA on proteins regulating cell cycle and survival As illustrated in Fig. 10 , the proteins associated with cell cycle (p21, cyclin D1, and CDK4), cell survival (p53, Bcl-2, and caspase-3), and cell migration (HMGB1) were expressed and easily detectable by immunoblotting in the two studied cancer cell lines (H1975 and HCC827). The suppression of TIFA by siRNA resulted in significant upregulation of p53 and increased levels of cleaved caspase-3 (p < 0.05, Fig. 10 ). In contrast, this inhibitory effect caused considerable downregulation of Bcl-2 protein (p < 0.05, Fig. 10) . Similarly, the inhibition of the expression of TIFA by siRNA led to a substantial reduction in the levels of cyclin D1 and CDK4 (p < 0.05, Fig. 10 ), but contributed to a significant increase in p21 levels (p < 0.05, Fig. 10 ). In addition, HMGB1 protein was significantly more inhibited in the H1975 (Fig. 10A and C) and HCC827 ( Fig. 10B and D) cells lacking TIFA than in the control cells (p < 0.05, Fig. 10) .
Next, we used immunoblotting to investigate the role of TIFA on the regulation of the nuclear transcription factor-kappa (NF-κB) and its inhibitor (IκB).As can be seen in Fig. 10 , positive staining of p-IKKß and p-p65 was detected in the two cancer cell lines (H1975: Fig.  11A and C; HCC827: Fig. 11B and D) as evidenced by the phosphorylation of IKKß (p-IKKß), IκBα (p-IκBα), and p-65 (p-p65). However, the levels of p-IKKß, p-IκBα, and p-p65 were significantly decreased in the cells transfected with TIFA-siRNA (p < 0.05, Fig. 11 ). 
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Discussion
In the present study, we investigated the expression of TIFA in lung cancer tissues and its role in the mediation of cancer cell survival and invasion. Our findings showed that the expression of TIFA in the lung cancer tissues was significantly higher than that in the adjacent healthy tissues. Moreover, the overall survival rate was considerably lower in the lung cancer patients with positive expression of TIFA than in the patients with negative TIFA expression. The suppression of TIFA by siRNA in the lung cancer cell lines resulted in significant inhibition of cell proliferation and migration but significantly increased apoptosis. In addition, the inhibition of TIFA in the lung cancer cell lines caused an increase in the levels of p53, p21, and cleaved-caspase-3, but decreased those of Bcl-2, cyclin D1, CDK4, and HMGB1. The phosphorylation of IKKß, IκBα, and p-65 was significantly suppressed in the lung cancer cell lines (H1975 and HCC827) after TIFA silencing by siRNA. These findings indicate that TIFA is associated with the overall survival rate of lung cancer patients and might increase lung cancer cell survival and invasion via inhibiting the apoptosis of lung cancer cells.
Lung cancer is the leading cause of cancer-associated death and the second most common newly diagnosed cancer in the world [1, 16] . In China, the mortality of lung cancer has been increasing over the last decades [17] , which is partially due to the lack of a specific biomarker or effective detection methods for its early diagnosis. Thus, biomarkers and targeted therapy of lung cancer has been extensively studied in the recent years. In the current study, we investigated the expression of TIFA in lung cancer tissues and its potential role in the prediction of patient outcomes. We found that the expression of TIFA was significantly increased in the lung adenocarcinoma tissues, and the TIFA-positive patients had a survival rate that was significantly lower than that of the lung cancer patients with negative TIFA expression. Based on these findings, we can speculate that the higher TIFA protein level in the lung cancer tissue could also serve as a novel biomarker that predicts the clinical outcome of patients with lung adenocarcinoma.
TIFA is a TRAF6-interacting protein, which was identified and first reported by Takatsuna et al. in 2003 [10] . Specifically, TIFA activates NF-κB and JNK by linking TRAF6 to IRAK-1 in the IL-1 pathway [10] . TRAFs are a family of proteins that participate in the signal transduction of TNF-α and IL-1 receptor/Toll-like receptor (IL-1R/TLR) super-families, and high expression of TRAF6 has been reported in lung cancer patients [18] [19] [20] [21] . TIFA seems to be involved in the regulation of the general response to pro-inflammatory stress though LPD-mediated signaling [22] . However, controversial results have been obtained in studies on the association of TIFA and cancer cell survival and proliferation. For example, Wei et al. 
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry reported that TIFA was expressed in acute myeloid leukemia (AML), and suppression of TIFA in AML cell lines by siRNA successfully decreased the leukemic cell growth and chemotherapy resistance [15] . By contrast, Shen et al. reported that the expression of TIFA in hepatocellular carcinoma (HCC) cells was lower than that in normal liver control cells; furthermore, the reconstitution of TIFA expression promoted the apoptosis of the HCC cells [14] . Conversely, here we report that the expression of TIFA in four lung cancer cell lines (A549, H1299, H1975, and HCC827) was higher than that in immortalized normal bronchial epithelial cells (BEAS2B). Furthermore, the suppression of TIFA by siRNA in the lung cancer lines resulted in significant inhibition of cell proliferation and ability of cell migration. These findings suggest that the role of TIFA vary in different tissue types of cancer cells; that is, while it exerts tumor-suppressive effects in hepatocellular carcinoma, oncogenic influence is established in lung cancer and hematopoietic malignancies.
While the precise causes and mechanisms of the aforementioned difference remain to be further investigated, the regulation of apoptosis by TIFA may play a key role in the survival of cancer cells. In this content, TIFA interacts with TRAF6 and modulates the oligomerization and ubiquitination of TRAF6 to activate the IκB kinase (IKK) complex, followed by subsequent phosphorylation and ubiquitination-dependent degradation of the inhibitor of κB (IκB), resulting in nuclear translocation of NF-κB, which activates downstream factors [11] .
NF-κB controls various aspects of the biological responses in a variety of cells, including immune responses, as well as cell survival, proliferation, and differentiation [23] . An increasing number of recent evidence indicates that NF-κB is aberrantly activated and cross-talks with other signaling molecules and pathways in chronic inflammation and a spectrum of malignancies [24] . Consistently, the phosphorylation of p65 in cancer cells was shown to protect tumor cells from apoptosis and increase their resistance to chemotherapy and ionizing radiation through regulation of the balance between pro-apoptotic and antiapoptotic factors [25, 26] . In line with this concept, the role of NF-κB and its downstream molecules in the modulation of lung cancer cell cycle and survival was explored in this study. In agreement with previous reports [15, 27] , we established that the silencing of TIFA promoted apoptosis and inhibited the cell migration of the lung cancer cell lines. Moreover, it attenuated the phosphorylation of IKK, IκB, and p65, and decreased the levels of Bcl-2, cyclin D1, and CDK4, but increased those of p21, p53, and cleaved caspase-3. These findings suggest that TIFA promotes lung cancer cell survival presumably through constitutive phosphorylation of the proteins involved in the NF-κB signaling pathway; it subsequently stimulates the pro-survival responses and activates anti-apoptotic signals.
Nevertheless, the current study has some limitations. First, the number of lung cancer patients was small. Second, this investigation was a retrospective study. Thus, prospective studies with larger numbers of cases and double-blinded control studies are required to further confirm the current findings. Third, Annexin-V assay was used in the present study to assess apoptosis, but Annexin-V detection can be used only to evaluate the early events in the process of apoptosis (the abnormal permeability and injury of the cell membrane). However, it does not detect the late-stage events of apoptosis, including DNA damage and break, which could only be detected by TUNEL and COMET assays. Finally, the "normal" lung tissues used for the comparative analysis of TIFA expression by immunohistochemistry were from the adjacent "normal" lung tissues of the same lung cancer patients, which might not have truly represented the normal lung tissue.
Taken together, the results of the present study reveal that the expression of TIFA in lung cancer tissues is higher than that in the adjacent normal lung tissues. In addition, TIFA was constitutively expressed in the lung cancer cell lines not only at the protein level, but also at the transcriptional level, with statistically significant higher values than those in the normal bronchial epithelial cell line. It is noteworthy that the patients with positive TIFA expression had significantly lower overall survival rates. The suppression of TIFA in the lung cancer cell lines by siRNA resulted in significant attenuation of cell proliferation and migration, as well as promotion of cancer cell apoptosis and cell-cycle arrest. Additionally,
Cellular Physiology and Biochemistry NF-κB (p65) phosphorylation was detected in the lung cancer cell lines, and the suppression of TIFA caused attenuation of p65 phosphorylation. The inhibition of TIFA by siRNA also led to alteration of apoptosis-and cell cycle-associated protein levels, including p53, caspase-3, Bcl-2, p21, cyclin D1, and CDK4. These findings suggest that TIFA may act as an anti-apoptotic factor in lung cancer cells and can thus serve as a biomarker for the prediction of lung cancer survival.
